Fill & Finish Resource Center
INTERPHEX 2012: Catalent's Jon Arnold Discusses the Next Generation of Blow-Fill-Seal
Blow-Fill-Seal is an established technology for pharmaceutical aseptic processing, but is diversifying into new applications, especially those catered to biologics manufacturing. At Interphex 2012 in New York City, Jonathan Arnold, VP and GM for Sterile Technologies for Catalent, talks with Paul Thomas about new wrinkles and applications in BFS, including liquid single-unit dose.
Implementing Disposable Cleanroom Apparel into the Manufacturing Process
In the case of disposable cleanroom apparel the benefits can include an easier gowning process, elimination of variability in filtration performance that can result from reusing apparel, less waste and improved levels of contamination control.
Striving for a Better Prefilled Syringe
West and Vetter look to meet the needs of parenteral manufacturers demanding new, safer syringe options.
Split Decisions: Tablet Scoring Under More Scrutiny
FDA provides more direction as questions arise about dosage consistency.
White Papers: In Depth Research
Best Practices from Baxter BioPharma: Optimizing Lyophilization and the Empirical Path to Cycle Development
Author: Baxter BioPharma
Using empirical, or science-based, freeze-drying approaches versus trial and error can help you navigate potential commercialization roadblocks.
Cartridge Filtration in the Production of Pharma Grade Water
Cartridge filtration can be a reliable, efficient means of producing bulk pharmaceutical grade water. This detailed paper from 3M illustrates its effective use for some of the most critical applications: the removal of particulates that might contaminate water systems, eliminating Pseudomonades and other microorganisms, reducing endotoxins, and protection of storage tanks during draw-down.
Increasing Tablet Press Productivity Using Segmented Turret Technology
Author: Fette America
Surveys of tablet press users reveal that machines with segmented turrets increase output and reduce set-up and cleaning time over conventional presses and previous turret technologies. This paper will discuss survey data from drug manufacturers using the technology and quantify some of the benefits over conventional press technologies.
Where and What to Test: From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product
This white paper focuses on what many consider the most critical part of a biological drug product’s manufacturing life cycle: going from the purified bulk drug substance (“PBDS”) to the sterile final drug product (“FDP”). Specifically, the white paper discusses establishing the testing “where and when” (and in some instances the “why”) for manufacturing formulation and fill/finish activities and how the approach is also applicable, for the most part, to small molecule drug products formulation and fill/finish.